CTXR - Citius Pharmaceuticals, Inc. Stock Price and Quote

CTXR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	8.40%	Shs Outstand	146.21M	Perf Week	17.45%
Market Cap	165.51M	Forward P/E	1.22	EPS next Y	0.96	Insider Trans	0.00%	Shs Float	133.82M	Perf Month	0.86%
Income	-28.00M	PEG	-	EPS next Q	-0.04	Inst Own	11.10%	Short Float / Ratio	8.56% / 13.75	Perf Quarter	48.99%
Sales	-	P/S	-	EPS this Y	-2.10%	Inst Trans	-8.45%	Short Interest	11.45M	Perf Half Y	-3.31%
Book/sh	0.69	P/B	1.70	EPS next Y	123.30%	ROA	-23.60%	Target Price	7.00	Perf Year	-34.64%
Cash/sh	0.26	P/C	4.49	EPS next 5Y	-	ROE	-26.00%	52W Range	0.77 - 2.01	Perf YTD	48.10%
Dividend	-	P/FCF	-	EPS past 5Y	34.40%	ROI	-	52W High	-41.79%	Beta	1.40
Dividend %	-	Quick Ratio	9.30	Sales past 5Y	-	Gross Margin	-	52W Low	51.95%	ATR	0.07
Employees	21	Current Ratio	9.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	58.90	Volatility	6.24% 6.52%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	61.10%	Profit Margin	-	Rel Volume	1.09	Prev Close	1.10
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	832.65K	Price	1.17
Recom	2.00	SMA20	11.58%	SMA50	-2.05%	SMA200	6.15%	Volume	934,391	Change	6.36%

Nov-30-21

Initiated

Maxim Group

Buy

Mar-30-23 08:30AM	Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company PR Newswire +6.36%
Mar-27-23 09:52AM	When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? Simply Wall St.
Mar-13-23 09:15AM	Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank PR Newswire -5.61%
Mar-08-23 08:30AM	Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference PR Newswire
Feb-10-23 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update PR Newswire
10:30AM	Loading…
Feb-06-23 10:30AM	Here Are 2 Ways I'm Playing the Market With Small-Cap Stocks TheStreet.com
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference ACCESSWIRE
Jan-16-23 07:09AM	Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation Simply Wall St.
Jan-11-23 08:30AM	Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 PR Newswire +7.10%
Dec-28-22 09:35AM	After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR) Zacks
Dec-22-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update PR Newswire
Dec-01-22 07:30AM	Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma PR Newswire +5.13%
Nov-21-22 08:00AM	Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program PR Newswire
Nov-09-22 08:30AM	Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting PR Newswire
Oct-18-22 08:30AM	Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022 PR Newswire
07:59AM	Loading…
07:59AM	Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook Simply Wall St.
Oct-06-22 04:30PM	Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 PR Newswire
Sep-28-22 08:30AM	Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma PR Newswire
Sep-23-22 06:48AM	Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings Benzinga
Sep-22-22 04:30PM	Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial PR Newswire
Sep-15-22 08:30AM	Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute PR Newswire
Sep-08-22 04:30PM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire +6.40%
Sep-07-22 08:30AM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire
Aug-11-22 04:31PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update PR Newswire +13.33%
Aug-09-22 07:24AM	Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely Simply Wall St. -7.77%
Jul-12-22 08:07AM	Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire
May-25-22 10:13AM	Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm Benzinga
08:47AM	Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company PR Newswire
May-18-22 09:30AM	Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022 PR Newswire
May-12-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update PR Newswire
07:34AM	Loading…
May-11-22 07:34AM	Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Shift From Loss To Profit Simply Wall St. -13.48%
May-10-22 11:10AM	10 Penny Stocks to Buy in May Insider Monkey +8.31%
May-08-22 09:00AM	3 Reddit Stocks to Buy in May InvestorPlace
May-06-22 09:37AM	Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally PR Newswire +6.86%
May-03-22 10:06AM	Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones PR Newswire +6.33%
Apr-26-22 08:30AM	Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids PR Newswire
Apr-14-22 09:25AM	Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022 PR Newswire
Apr-13-22 09:25AM	Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates PR Newswire
Apr-07-22 09:57AM	Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study Zacks -8.19%
Apr-06-22 08:14AM	Shares of Citius jump 18% on new data for experimental lymphoma drug MarketWatch -7.07%
06:50AM	Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission PR Newswire
Mar-29-22 10:18AM	These 10 Penny Stocks are Trending on Reddit Insider Monkey
Mar-03-22 09:15AM	Citius Pharmaceuticals, Inc. to Present at Upcoming March 2022 Conferences PR Newswire
Mar-02-22 04:12AM	Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Invest In Growth? Simply Wall St.
Feb-15-22 09:15AM	Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids PR Newswire +5.84%
Feb-10-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update PR Newswire
Jan-04-22 09:00AM	Citius Pharmaceuticals, Inc. to Present at Upcoming Virtual Conferences PR Newswire
Dec-15-21 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update PR Newswire
Dec-06-21 09:15AM	Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire +7.95%
Dec-02-21 05:17AM	Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Simply Wall St.
Nov-05-21 09:15AM	Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls PR Newswire
Oct-25-21 09:15AM	Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients PR Newswire
Oct-13-21 11:38AM	Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777) PR Newswire
Oct-06-21 10:40AM	Citius Pharmaceuticals to Present at Upcoming October Investor Conferences PR Newswire
Oct-04-21 12:31PM	10 Reddits WallStreetBets Stocks Under $5 Insider Monkey
Oct-01-21 08:30AM	Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur PR Newswire
Sep-23-21 12:12PM	10 Best Micro-Cap Stocks to Invest In Insider Monkey
Sep-16-21 10:38AM	10 New Penny Stocks Redditors are Buying Insider Monkey
Sep-14-21 10:06AM	Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021 PR Newswire -5.26%
Sep-08-21 11:34AM	Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy Zacks
09:15AM	Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15 PR Newswire
Sep-07-21 07:30AM	Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications PR Newswire
Aug-12-21 04:30PM	Citius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update PR Newswire
Aug-04-21 10:34AM	Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs Benzinga
Aug-03-21 04:29PM	10 Best Penny Stocks Popular on Reddit Insider Monkey
Jul-20-21 07:17AM	Could Citius Pharmaceuticals Be a Millionaire-Maker Stock? Motley Fool
Jul-07-21 07:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Citius Pharmaceuticals, Inc. - CTXR PR Newswire
12:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Citius Pharmaceuticals, Inc. (CTXR) Investigation ACCESSWIRE
09:20AM	Citius Pharmaceuticals, Inc. Provides First Half 2021 Business Update, Highlights Upcoming Milestones PR Newswire
08:05AM	Are Options Traders Betting on a Big Move in Citius Pharmaceuticals (CTXR) Stock? Zacks
Jul-01-21 12:56PM	Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today Motley Fool -25.29%
09:00AM	Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned PR Newswire
07:51AM	Citius Pharma Tumbles as Panel Suggests Antibiotic Trial Continue TheStreet.com
Jun-23-21 07:51AM	Is It Too Late to Buy Citius Pharmaceuticals Stock? Motley Fool
Jun-21-21 06:50PM	Is Citius Pharmaceuticals, Inc. (CTXR) A Good Stock To Buy? Insider Monkey +14.63%
Jun-17-21 06:00AM	Influencers with Andy Serwer: David Ricks Yahoo Finance Video +7.78%
06:00AM	By next summer we'll have enough vaccines to vaccinate the world: Eli Lilly CEO Yahoo Finance Video
Jun-16-21 05:55PM	Top 3 Penny Stocks to Buy Right Now for Your 2021 Summer Watchlist Benzinga
02:43AM	We're Hopeful That Citius Pharmaceuticals (NASDAQ:CTXR) Will Use Its Cash Wisely Simply Wall St.
Jun-15-21 09:20AM	Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS PR Newswire +17.45%
Jun-08-21 02:11PM	Citius Pharma Plans Interim Analysis for Mino-Lok By End of June Benzinga
09:00AM	Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial PR Newswire
Jun-07-21 09:00AM	Citius Pharmaceuticals to be Added to Russell 2000® Index PR Newswire +9.44%
Jun-03-21 08:18AM	Citius Pharmaceuticals Introduces Milo-Lok Benzinga
May-25-21 02:52PM	Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting PR Newswire
May-18-21 09:29AM	Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy PR Newswire +8.63%
May-17-21 12:30PM	Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations PR Newswire
May-13-21 07:30AM	Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update PR Newswire -9.57%
May-11-21 04:30PM	Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18 PR Newswire
May-04-21 09:15AM	Citius Pharmaceuticals to Present Mino-Lok® and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13 PR Newswire
Apr-29-21 09:37AM	Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar PR Newswire +7.11%
Apr-22-21 04:30PM	Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview PR Newswire +5.88%
Apr-19-21 08:53AM	Citius Thrives in 2021 with Critical Care Solutions for ARDS Associated with COVID-19 Benzinga -5.20%
Mar-23-21 09:00AM	Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25 PR Newswire
Mar-04-21 10:11AM	Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10 PR Newswire -7.81%
Feb-19-21 04:47PM	Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire +32.05%
11:34AM	CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge InvestorPlace
Feb-17-21 12:28AM	Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire -11.83%
Feb-16-21 09:15AM	Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021 PR Newswire +24.26%
Feb-08-21 08:35AM	Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing PR Newswire

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience